Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD-1 (CD279) |
| Clinical data | |
| Other names | PDR001 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
This drug is being developed by Novartis. As of 2018[update], spartalizumab is undergoing Phase III trials.[2]
References
edit- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ^ Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020). "Antibodies to watch in 2020". mAbs. 12 (1): 1703531. doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |